colorectal tumor
Conditions
Interventions
Patient-controlled intravenous analgesia group (PCIA group):Intravenous analgesia was used. The analgesic formula was sufentanil 200ug+ Ondansetron 8mg, with a total capacity of 100ml
Ultrasound-guided transabdominal muscle plane block with high concentration group (TAP5 group):An ultrasound-guided transversal plane block was performed on both sides, with each side injected with 0.
Ultrasound-guided erector spinae plane blcok with high concentration group (ESPB5 group):An ultrasound-guided vertical spinal muscle plane block was performed on both sides, each side was injected wit
High concentration group of epidural block analgesia (EB5 group):An epidural puncture was performed between T7-T8 and an injection of 0.5% ropivacaine (AstraZeneca, UK) 7ml was performed
Ultrasound-guided transabdominal muscle plane block with low concentration group (TAP3 group):An ultrasound-guided transversal plane block was performed on both sides, and 0.3% ropivacaine (AstraZenec
Ultrasound-guided erector spinae plane block with low concentration group (ESPB3 group):An ultrasound-guided erector spinae plane block was performed on both sides, with each side at the T8 transverse
Epidural block analgesia with low concentration group (EB3 group):The epidural puncture was performed between T8-T9 and injected with 0.3% ropivacaine (AstraZeneca, UK) 7ml
Combined with dexmedetomidine for ultrasound-guided transabdominal muscle plane block group (TAPDEX group):An ultrasound-guided transversal muscle plane block was performed on both sides, with 0.5% ro
Sponsors
Cancer Hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Aged 18-65 years; (2) ASA I ~ II level; (3) Patients will undergo selective laparoscopic radical resection for colorectal cancer.
Exclusion criteria
Exclusion criteria: (1) Severe cardiopulmonary or other organs diseases; (2) Body mass index (BMI) greater than 30 kg/m2 or less than 18kg/m2; (3) Severe complications occurred after the operation, such as multiple bleeding requiring reoperation; (4) Allergic to local anesthetic drugs; (5) There are infected patients in the puncture site of abdominal and transverse muscle plane block and vertical spine muscle plane block; (6) Previous history of abdominal surgery (surgical scar may affect local anesthetic diffusion); (7) The abdominal surgical site is numb due to peripheral neuropathy or abnormal sensation in the innervated cutaneous area; (8) Patients with communication disorders (language/physical defects) and unable to correctly understand the Visual analogue Scale (VAS); (9) Patients with chronic pain including chronic abdominal pain; (10) Patients with history of mental illness (11) Patients with history of drug abuse, or recent use of analgesic drugs, including opiates, nonsteroidal anti-inflammatory drugs (NSAIDs), or Traditional Chinese medicines.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative pain intensity score;Indicators related to inflammatory response;Indicators related to immune function; | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative sedation score;Pain control satisfaction score;ncidence of postoperative nausea and vomiting;Complications related to analgesia; | — |
Countries
China
Contacts
Public ContactQiang Wang
Outcome results
None listed